IRVINE, CA, and LIEGE, BELGIUM – February 18, 2013 – MDxHealth SA , a leading molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, today announced the results of two studies of the ConfirmMDx for Prostate Cancer test presented at the ASCO Genitourinary Cancers … (more)
